Collectively, the present results suggest that the oral administration of RCE effectively attenuates tumor growth in humanized PD-1 mice, indicating that RCE could be utilized as a potential candidate agent for cancer therapeutics targeting PD-1 and PD-L1. The gene discussed is CD274; the disease is cancer.